

Inhibition of Cancer Cell Proliferation by PPAR γ Is Mediated by a Metabolic Switch that Increases Reactive Oxygen Species Levels

Nishi Srivastava,^{1,7} Rahul K. Kollipara,^{1,7} Dinesh K. Singh,^{1,8} Jessica Sudderth,² Zeping Hu,² Hien Nguyen,^{2,9} Shan Wang,¹ Caroline G. Humphries,¹ Ryan Carstens,³ Kenneth E. Huffman,³ Ralph J. DeBerardinis,^{1,2,4} and Ralf Kittler^{1,4,5,6,*}

¹Eugene McDermott Center for Human Growth and Development

²Children's Medical Center Research Institute

³Hamon Center for Therapeutic Oncology Research

⁴Simmons Comprehensive Cancer Center

⁵Department of Pharmacology

⁶Green Center for Reproductive Biology Sciences

The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA

⁷Co-first authors

⁸Present address: Department of Neurology and Neurotherapeutics, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA

⁹Present address: Proteomics and Mass Spectrometry Facility, University of Massachusetts Medical School, Shrewsbury, MA 01545, USA

*Correspondence: ralf.kittler@utsouthwestern.edu

<http://dx.doi.org/10.1016/j.cmet.2014.08.003>

SUMMARY

The nuclear receptor peroxisome-proliferation-activated receptor gamma (PPAR γ), a transcriptional master regulator of glucose and lipid metabolism, inhibits the growth of several common cancers, including lung cancer. In this study, we show that the mechanism by which activation of PPAR γ inhibits proliferation of lung cancer cells is based on metabolic changes. We found that treatment with the PPAR γ agonist pioglitazone triggers a metabolic switch that inhibits pyruvate oxidation and reduces glutathione levels. These PPAR γ -induced metabolic changes result in a marked increase of reactive oxygen species (ROS) levels that lead to rapid hypophosphorylation of retinoblastoma protein (RB) and cell-cycle arrest. The antiproliferative effect of PPAR γ activation can be prevented by suppressing pyruvate dehydrogenase kinase 4 (PDK4) or β -oxidation of fatty acids *in vitro* and *in vivo*. Our proposed mechanism also suggests that metabolic changes can rapidly and directly inhibit cell-cycle progression of cancer cells by altering ROS levels.

INTRODUCTION

A hallmark of cancer is the reprogramming of glucose, lipid, and glutamine metabolism to provide energy and substrates for biosynthesis, which are required for proliferation and survival of transformed cells (DeBerardinis et al., 2008; Hanahan and Weinberg, 2011; Vander Heiden et al., 2009). A classical metabolic change in cancer is the increased consumption of glucose and inhibition of pyruvate oxidation, leading to high rates of lactate secretion even under normoxic conditions ("Warburg effect") (Hsu and Sabatini, 2008; Koppenol et al., 2011; Warburg, 1956). More recently, glutamine has been identified as a critical

nutrient for cancer cells to replenish TCA cycle metabolites for the biosynthesis of lipids and mitochondrial ATP production (DeBerardinis et al., 2007; Hensley et al., 2013), complementing the altered state of glucose metabolism.

Therapeutic strategies harnessing altered metabolic properties of cancer cells are currently focused on developing specific inhibitors against key metabolic enzymes, such as glutaminase (Le et al., 2012; Robinson et al., 2007; Thangavelu et al., 2012) and PKM2 (Christofk et al., 2008; Vander Heiden et al., 2010). In principle, the activation or inhibition of transcriptional master regulators of metabolic processes presents another promising strategy to target cancer metabolism and may achieve a more selective response. In this vein, our group recently found that PPAR γ is expressed at high levels in a subset of non-small cell lung cancer cells (Jeong et al., 2012), where its activation with thiazolidinediones (TZDs) causes growth inhibition both *in vitro* and *in vivo*. Also, growth-suppressing effects of PPAR γ and TZDs have been shown for a variety of other cancers (reviewed in Koeffler, 2003; Peters et al., 2012). Considering the known functions of PPAR γ in orchestrating glucose and lipid metabolism (Kliewer and Willson, 1998; Willson et al., 2001), it is conceivable that the antitumorigenic effects of PPAR γ may be mediated in part through the activation of a genetic program that affects metabolism of cancer cells. Therefore, understanding the molecular basis of the effects of PPAR γ activation on lung cancer cells may also provide general mechanistic insights into the impact of metabolic changes on cancer cell growth. In the present study, we sought to elucidate the molecular actions of PPAR γ in lung cancer cells by integrating the analysis of genomic functions of PPAR γ with biochemical follow-up analyses and metabolic profiling of changes caused by PPAR γ activation.

RESULTS

PPAR γ Regulates the Expression of Genes Implicated in Metabolism and Proliferation in Lung Cancer Cells

To characterize the genetic program regulated by PPAR γ , we analyzed the cistrome of this transcription factor and the effects




Figure 1. Characterization of the PPAR γ Cistrome in Lung Cancer Cell Lines

(A) Density plots of ChIP-seq reads for PPAR γ -occupied regions in NCI-H2347 and NCI-H1993 cells. The x axis depicts 2 kb 5' and 3' to the predicted peak summits (0). The y axis depicts read coverage.

(B) De novo motif analysis for PPAR γ -occupied regions. Shared PPAR γ occupied regions of NCI-H2347 and NCI-H1993 were analyzed with MEME. The two most significant motifs are shown. These motifs have the most significant similarity to the known PPAR γ ::RXRA or Fos/AP1 motif, respectively.


(C) Known ENCODE and JASPAR transcription factor motif enrichment in PPAR γ bound regions. Enrichment scores and p values were calculated based on the distribution of each motif in the genome using 75,000 simulations.

(D) PPAR γ binding regions near the transcription start sites of putative PPAR γ target genes (*PDK4* and *PLIN2*), as depicted in the UCSC Genome Browser. The x axis depicts genome coordinates; the y axis depicts ChIP-seq read density (red: NCI-H2347, blue NCI-H1993) normalized with respect to input reads.

of PPAR γ activation by TZDs on transcription on a genome-wide scale. For the cistrome analysis, we used chromatin immunoprecipitation followed by deep sequencing (ChIP-seq) with NCI-H2347 and NCI-H1993 lung adenocarcinoma cells, which express PPAR γ at high levels and whose growth is inhibited by TZDs such as pioglitazone and troglitazone (Jeong et al., 2012). We found 2,225 regions in NCI-H2347 cells and 1,419 in NCI-H1993 cells with a significantly increased occupancy for PPAR γ (Figure 1A; Table S1 available online). Of these binding sites, 484 were shared by both cell lines. De novo motif analysis of the PPAR γ binding regions identified a canonical PPAR γ motif consisting of two direct hexanucleotide repeats with a one nucleotide spacer (DR1) as the most significant motif (Figure 1B; Table S2), which is similar to the motif elicited for PPAR γ occupied regions in mouse 3T3-L1 cells (Lefterova et al., 2008; Nielsen et al., 2008). The second most significant motif identified by MEME is highly similar to the AP-1 (Fos) motif, which suggests that PPAR γ target genes in lung adenocarcinoma cell lines may be coregulated by AP-1 transcription factors. The canonical PPAR γ motif was also the most highly and significantly enriched motif when we compared the frequency of known transcription factor motifs in PPAR γ -bound regions with respect to their frequency distribution in the human genome (Figure 1C; Table S3). This analysis identified additional enriched motifs of other transcription factors such as Nrf2 (NFE2L1), Forkhead, and CEBP family proteins, which are recruited to PPAR γ binding regions (Lefterova et al., 2008). These findings demonstrate the presence of bona fide,

direct binding sites of PPAR γ in the genome of lung cancer cells. When we analyzed the putative PPAR γ target genes (defined as genes whose transcription start sites are within 100 kb to PPAR γ occupied loci) shared by both NCI-H2347 and NCI-H1993 cells (e.g., the established PPAR γ target genes *PDK4* and *PLIN2*) (Lefterova et al., 2008; Nielsen et al., 2008) (Figure 1D) for enrichment in functional annotation categories, we found biological processes that are relevant for known metabolic functions of PPAR γ (Figure 2A). Importantly, we found a highly significant enrichment for genes implicated in several aspects of lipid metabolism among the predicted PPAR γ targets.

We next combined the analysis of the PPAR γ cistrome with the analysis of the transcriptional effects of PPAR γ activation by TZDs. For that purpose, we performed a time course analysis of gene expression, where we profiled the effects of pioglitazone treatment on the transcriptome of NCI-H2347 cells after 12, 24, and 48 hr of treatment (Figure 2B; Table S4). We identified 1,781 genes whose expression was either significantly upregulated or downregulated at any of the three time points (adjusted $p \leq 0.05$; fold change ≥ 2). We used k means clustering to group genes into five clusters with similar expression profiles. For the obtained clusters, we analyzed PPAR γ binding site enrichment (Figure 2C). We found that genes in the “Early Up” cluster whose expression is upregulated after 12 hr are most significantly enriched for PPAR γ target genes predicted by ChIP-seq and thus likely present putative direct targets of PPAR γ . Genes whose expression is upregulated after 24 or 48 hr were less significantly enriched among genes with PPAR γ binding sites, and genes whose expression was decreased showed the least enrichment among PPAR γ direct targets, suggesting that these genes are not directly regulated by PPAR γ . Next, we performed gene set



(legend on next page)

enrichment analysis (GSEA) (Subramanian et al., 2005) to elucidate the gene programs regulated by PPAR γ . Among the significantly enriched gene sets (Figure 2D), we found that genes implicated in lipid metabolism such as fatty acid beta oxidation were among the early upregulated genes (e.g., *PDK4* and *PLIN2*), while genes implicated in cell-cycle progression (e.g., *UBE2C*, *BUB1*, *PRC1*, *CDK2*, and *CDK6*) were enriched among the genes whose expression is downregulated late (after 48 hr) and which are not enriched for PPAR γ target genes. Furthermore, we found genes implicated in oxidative stress response (e.g., *SOD3*, *CAT*, and *MUC1*) among the genes that were upregulated at later time points. Collectively, these findings suggest that PPAR γ activation causes the direct and early upregulation of genes controlling lipid metabolism.

PPAR γ Activation Inhibits Cell Proliferation by an Reactive-Oxygen-Species-Dependent Mechanism

We hypothesize that the increased expression of these genes causes a change in cancer cell metabolism, which in turn causes oxidative stress and ultimately leads to cell-cycle arrest in G1. Hence, there was a reduction in transcript levels for genes that are expressed in the S and G2/M phases of the cell cycle. To test this hypothesis, we analyzed the effects of pioglitazone treatment on cell-cycle progression and the levels of reactive oxygen species (ROS) in the lung cancer cell lines. Using DNA content analysis by fluorescence-activated cell sorting (FACS), we found that pioglitazone treatment caused G1 arrest in both NCI-H2347 and NCI-H1993 cells (Figures 3A and 3B) but not in NCI-H1299 and NCI-H1395 cells (Figures S1A and S1B), which are essentially PPAR γ negative (Jeong et al., 2012). The pioglitazone-induced cell-cycle arrest coincided with a marked reduction in the levels of phosphorylated RB in the NCI-H2347 and NCI-H1993 cells within 24 hr of treatment (Figure 3C), but not in the PPAR γ -negative NCI-H1299 and NCI-H1395 cells (Figure S1C). We found that pioglitazone-induced RB hypophosphorylation was PPAR γ dependent, as PPAR γ knockdown with two independent siRNAs prevented a reduction of phosphorylated RB by pioglitazone in NCI-H2347 cells (Figure S1D). Also, we observed RB hypophosphorylation when we treated NCI-H2347 and NCI-H1993 cells with an alternative TZD, troglitazone (Figure S1E). Pioglitazone treatment of NCI-H2347 cells resulted in decreased BrdU incorporation in a time-dependent manner (Figure S1F) but did not cause apoptosis, as PARP or Caspase-3 cleavage (Figure S1G) were not increased. Thus, pioglitazone treatment appears to inhibit cell proliferation in an RB-dependent manner without inducing apoptosis. We found that pioglitazone treatment of the PPAR γ -expressing breast cancer

cell lines HCC-1954 and HCC-1187 (but not of the PPAR γ -negative breast cancer cell lines T-47D and HCC-1143) also resulted in RB hypophosphorylation (Figure S1H), which suggests that our findings are applicable to other major cancer types.

Next, we tested if treatment of NCI-H2347 cells with H₂O₂ caused RB hypophosphorylation and found that low micromolar concentrations of H₂O₂ (>5 μ M) caused a dose-dependent decrease in the levels of phosphorylated RB (Figure 3D). To analyze the impact of PPAR γ activation on ROS levels, we used the fluorescent ROS probe DCFDA for FACS (Figure 3E) and found that pioglitazone markedly increased ROS levels in PPAR γ -positive NCI-H2347 (Figure 3F) and NCI-H1993 cells (Figures S2A and S2B) but not in the PPAR γ -negative NCI-H1299 and NCI-H1395 cells (Figures S2C–S2F). Likewise, pioglitazone markedly increased ROS levels in the PPAR γ -positive HCC-1954 and HCC-1187 breast cancer cells (Figures S2G–S2J) but not in the PPAR γ -negative T-47D and HCC-1143 cells (Figures S2K–S2N). The increase in ROS levels upon pioglitazone treatment could be rescued both by treatment with the antioxidant N-acetylcysteine (NAC) (Figure 3G) or PPAR γ knockdown by siRNAs (Figures S2O–S2R). Furthermore, we found ROS levels increased when we treated NCI-H2347 and NCI-H1993 cells with troglitazone (Figures S2S–S2V).

The above findings suggested that PPAR γ activation causes an increase in both ROS levels and RB hypophosphorylation. To corroborate this hypothesis, we performed two experiments. First, we tested if antioxidant treatment could prevent RB hypophosphorylation after pioglitazone treatment in PPAR γ -expressing cells. We found that NCI-H2347 cells cotreated with NAC or with another antioxidant, vitamin C, showed no decrease in phosphorylated RB levels upon pioglitazone treatment (Figure 3H). Likewise, NAC prevented RB hypophosphorylation by pioglitazone in HCC-1954 and HCC-1187 breast cancer cells (Figure S1I). Second, we tested if increased ROS levels were required for the growth inhibition observed for TZDs in vivo (Jeong et al., 2012). For this purpose, we tested the effects of NAC on pioglitazone-mediated inhibition of NCI-H2347 tumor xenograft growth. We found that NAC cotreatment significantly mitigated the antitumorigenic effects of pioglitazone ($p = 1 \times 10^{-4}$) (Figure 3I).

To pinpoint the mechanistic link between increased ROS levels and RB hypophosphorylation, we tested if active dephosphorylation of RB by the RB-dephosphorylating enzyme protein phosphatase 2A (PP2A) (Alberts et al., 1993; Avni et al., 2003) was required for the effect of pioglitazone on RB phosphorylation. We found that low nanomolar concentrations of okadaic acid, which achieves selective and effective inhibition of PP2A,

Figure 2. Genomic Functions of PPAR γ in Lung Cancer Cell Lines

(A) Concept map of PPAR γ targets predicted by ChIP-Seq. p values for enrichment between gene signature sets were calculated (hypergeometric test) and used to construct a network of significantly enriched signatures (FDR cut-off 1%). The node size corresponds to the number of genes in a signature set; the edge intensity correlates with the significance of enrichment between two signature sets.

(B) Time course analysis of gene expression for pioglitazone treatment. Heat map of log₂-transformed fold changes of 1,781 genes with significantly differential gene expression (cut-off: fold change ≥ 2 and adjusted p value ≤ 0.05) after 12, 24, or 48 hr of pioglitazone treatment. Hierarchical clustering was performed using Euclidean distance metric. Several genes are shown as examples for differentially expressed genes (*PDK4*, *SOD3*, *CAT*, *PLIN2*, *MUC1*, *UBE2C*, *BUB1*, *PRC1*, *CDK2*, and *CDK6*).

(C) Enrichment for PPAR γ direct targets in different gene expression clusters. Clusters defined by k means clustering and the significance of enrichment for PPAR γ direct targets as predicted by ChIP-seq was calculated for each cluster (hypergeometric test).

(D) GSEA for pioglitazone-regulated genes. Hierarchical clustering of normalized enrichment scores for gene sets that are significantly (FDR ≤ 0.05) over-represented in pioglitazone regulated genes.




Figure 3. PPAR γ Activation Inhibits Cell Proliferation by a ROS-Dependent Mechanism

(A and B) DNA content analysis of NCI-H2347 (A) and NCI-H1993 (B) cells after 24 hr of treatment with pioglitazone (Pio) or vehicle (DMSO) indicates a G1 arrest upon PPAR γ activation.

(C) Pioglitazone treatment causes a decrease in the levels of phosphorylated RB in both NCI-H2347 and NCI-H1993 cells within 24 hr.

(D) Hydrogen peroxide treatment causes a decrease in the levels of phosphorylated RB in NCI-H2347 within 24 hr.

(E–G) Pioglitazone treatment causes an increase in ROS levels in NCI-H2347 cells. FACS with DCFDA was performed after 12 hr treatment with vehicle (DMSO) (E) or pioglitazone (F) or pioglitazone and NAC (G). Note that the increase in ROS levels was completely blocked by cotreatment with NAC.

(H) NAC and vitamin C prevent the reduction in phosphorylated RB levels by pioglitazone in NCI-H2347 cells after 24 hr of treatment.

(I) Tumor growth inhibition by pioglitazone in vivo is ROS dependent. Mice xenografted with NCI-H2347 cells were treated upon appearance of tumors with pioglitazone, DMSO (vehicle), NAC, or a combination of pioglitazone and NAC (i.p.) every other day beginning on day 23 after cell injection. Error bars represent SEM.

prevented the increase in dephosphorylated RB after pioglitazone treatment (Figure S1J), suggesting that increased ROS levels activate PP2A catalytic activity.

To further validate the specificity and characterize the effects of TZDs on the growth of PPAR γ -expressing tumors, we generated NCI-H2347 cell lines that stably express two independent shRNAs targeting PPAR γ (shPPARG-1 and shPPARG-2, achieving \sim 70% PPAR γ knockdown) (Figure 4A) and a non-targeting shRNA (shNT) as negative control. We found that the growth of NCI-H2347 tumors with stable PPAR γ knockdown was not inhibited by pioglitazone treatment in vivo (Figure 4B). We further characterized the underlying cause of pioglitazone-mediated inhibition of tumor growth by analyses of xenograft tumor cell proliferation (Ki-67 staining) and apoptosis (TUNEL staining) (Figure 4C). We found that pioglitazone treatment dramatically reduced the percentage of Ki-67 positive (i.e., proliferating cells) in the shNT ($p = 0.0045$) but not in the shPPARG-1 and shPPARG-2 tumors (Figure 4D) ($p > 0.05$) and had no statistically significant effect on the percentage of apoptotic cells in either tumor (Figure 4E) ($p > 0.05$). Collectively, these findings suggest that PPAR γ causes metabolic changes that result in increased levels of ROS, which ultimately lead to active RB hypophosphorylation and thus inhibition of cancer cell proliferation.

our gene expression time course analysis. Among these genes, we found *pyruvate dehydrogenase kinase 4* (PDK4) as the most highly upregulated direct PPAR γ target gene. Using quantitative RT-PCR analysis, we found a 3.1-fold increase in PDK4 transcript levels in NCI-H2347 cells after 3 hr of pioglitazone treatment, which further increased to more than 10-fold higher levels after 12 hr (Figure 5A). PDK4 is a regulatory kinase that phosphorylates and thereby inhibits pyruvate dehydrogenase. Thus, PDK4 inhibits pyruvate oxidation and was shown to mediate the metabolic switch from glucose oxidation to fatty acid oxidation in normal tissues (Andrews et al., 1998; Holness et al., 2000; Hue and Taegtmeyer, 2009; Strand et al., 2012). Interestingly, upregulation of PDK4 expression was previously shown to inhibit cell proliferation of MCF-10A mammary epithelial cells (Grassian et al., 2011). Importantly, the same study found that PDK4 expression is markedly downregulated in many common solid tumors, including lung and breast cancer, suggesting that PDK4 may cause metabolic changes that inhibit tumor cell proliferation. We did not observe increased expression of any of the other three pyruvate dehydrogenase kinase genes (*PDK1*, *PDK2*, and *PDK3*) upon pioglitazone treatment (Figure 5B). In order to test the role of PDK4 in the induction of oxidative stress and RB hypophosphorylation by TZDs, we analyzed the effects of PDK4 knockdown by siRNAs or inhibition with the pyruvate

PDK4 and β -Oxidation Are Required for the Effects of Pioglitazone on ROS Levels and RB Phosphorylation

In order to identify metabolic regulators responsible for the antitumorigenic effects of PPAR γ activation, we analyzed the functions of genes whose expression was upregulated early by pioglitazone in




Figure 4. The Antitumorigenic Effect of Pioglitazone In Vivo Is Caused by Inhibition of Cell Proliferation and Is PPAR γ Dependent

(A) PPAR γ mRNA expression in NCI-H2347 cells stably expressing shNT (negative control), shPPARG-1, or shPPARG-2. PPAR γ transcript levels were determined by quantitative RT-PCR using B2M as a calibrator ($n = 3$; error bars represent SD).

(B) Mice xenografted with NCI-H2347 shNT, shPPARG-1, and shPPARG-2 cells were treated upon appearance of tumors with DMSO (vehicle) or pioglitazone every other day beginning on day 25 after cell injection. Error bars represent SEM. $n = 10$ for all treatment groups. Growth of the shNT tumors was inhibited by pioglitazone treatment ($p < 1 \times 10^{-5}$), but no such effect was observed for the shPPARG-1 and shPPARG-2 tumors ($p > 0.05$).

(C–E) Tumors were obtained at the end of the treatment course and stained for Ki-67, TUNEL, and DNA (propidium iodide) (scale bar is 10 μ m) (C). For quantification of Ki-67 positivity (D) and TUNEL positivity (E), two microscopic fields containing at least 100 cells each were analyzed for each treatment group. Error bars represent SD.




Figure 5. PDK4 and β -Oxidation Are Required for the Effects of Pioglitazone on ROS Levels and RB Phosphorylation

(A and B) PDK4 mRNA expression rapidly increases upon pioglitazone treatment (A), but expression of PDK1, PDK2, and PDK3 mRNA is not increased after 24 hr of pioglitazone treatment (B). PDK1, PDK2, PDK3, and PDK4 transcript levels in NCI-H2347 cells were determined by quantitative RT-PCR using B2M as a calibrator for a pioglitazone treatment time course (A) or after 24 hr of treatment (B) ($n = 3$; error bars represent SD).

(C–G) PDK4 knockdown by siRNA prevents the decrease in phosphorylated RB (C) and the increase in ROS levels ([D]–[G]) upon pioglitazone treatment. NCI-H2347 cells were transfected with two siRNAs targeting PDK4 or a non-targeting siRNA (siNT); after 48 hr the cells were treated with vehicle or pioglitazone for 24 (C) or 12 hr ([D]–[G]). Then the cells were analyzed by immunoblotting (C) or stained with DCFDA and assayed by FACS ([D]–[G]).

(legend continued on next page)




Figure 6. Tumor Growth Inhibition by Pioglitazone In Vivo Requires PDK Activity and Fatty Acid Oxidation

(A and B) Mice xenografted with NCI-H2347 cells were treated upon appearance of tumors with DMSO (vehicle), pioglitazone, DCA (A), trimetazidine (B), a combination of pioglitazone and DCA (A), or pioglitazone and trimetazidine (B) (i.p.) every other day beginning on day 25 after cell injection. Error bars represent SEM. $n = 10$ for all treatment groups. Both DCA and trimetazidine suppress the growth-inhibiting effects of pioglitazone ($p < 1 \times 10^{-5}$).

dehydrogenase kinase inhibitor dichloroacetate (DCA) on ROS levels and RB phosphorylation. We found that PDK4 knockdown (Figure S3A) reversed the effects of pioglitazone on RB phosphorylation (Figure 5C) and ROS levels (Figures 3D–3G) in NCI-H2347 and HCl-H1993 cells (Figures S3B and S3E–S3H), as did inhibition by DCA (Figures 5H–5K, S3C, and S3I–S3L). Next, we tested whether fatty acid oxidation was required for the increased ROS levels and RB hypophosphorylation by TZDs. For that purpose, we used trimetazidine, an inhibitor of acetyl-coenzyme A acyltransferase 2, which catalyzes the termi-

nal step of the β -oxidation cycle. This compound prevented RB hypophosphorylation by pioglitazone (Figure 5L and S3D) and the increase of ROS levels (Figures 5M–5O and S3M–S3P) by pioglitazone in NCI-H2347 and NCI-H1993 cells. We tested whether pioglitazone treatment affected mitochondrial superoxide generation directly using the superoxide fluorescent FACS probe MitoSOX. We observed no effect of pioglitazone on mitochondrial superoxide generation using antimycin A and rotenone as positive controls (Figures S3Q–S3T). We note that inhibition of NADPH oxidase, which is one major source of ROS by apocynin, prevented the increase in ROS levels by pioglitazone but also caused a slight reduction of ROS levels without pioglitazone treatment (Figures S3U–S3X).


To test the relevance of PDK4 and fatty acid oxidation on tumor growth inhibition by PPAR γ activation in vivo, we analyzed the effects of DCA (Figure 6A) and trimetazidine (Figure 6B) in NCI-H2347 xenograft experiments. We found that both compounds suppressed the growth-inhibiting effects of pioglitazone, which indicates a critical role of PDK4 and fatty acid oxidation in the antitumor effects of PPAR γ activation. Collectively, these findings suggest that the upregulation of PDK4, a key regulator of glucose and fatty acid utilization, is necessary for the increase in ROS levels that ultimately leads to RB hypophosphorylation and tumor growth arrest.

PPAR γ Activation Alters Glucose and Glutamine Metabolism in NCI-H2347 Cells to Culminate in Suppressed Glutathione Abundance

To pinpoint the metabolic effects of PPAR γ activation in cancer cells, we applied a suite of assays designed to interrogate key nodes of metabolic activity. Consistent with the known function of PDK4 in limiting pyruvate oxidation, examination of tissue culture medium revealed enhanced glucose consumption and lactate secretion in pioglitazone-treated cells (Figure 7A). Furthermore, culture with [U -¹³C]glucose (Figure 7B) revealed a suppressed production of citrate molecules (Figure 7C) and other TCA cycle metabolites (Figure 7D) containing two glucose-derived carbons ($m+2$), indicative of reduced PDH contribution to the acetyl-CoA pool. We next tested whether metabolism of glutamine, the predominant source of glutamate, was altered by pioglitazone. For this purpose, we pretreated cancer cells with pioglitazone for 6 or 12 hr prior to adding [U -¹³C] glutamine to the medium and followed the time course of labeling in the glutamate pool. Pioglitazone reduced the conversion rate of glutamine to glutamate (Figure 7E). Since glutamate is required for the synthesis of glutathione (GSH), a central component of cellular ROS detoxification, we tested whether pioglitazone affected the levels of GSH. We found that pioglitazone treatment resulted in a marked decrease of both reduced and total GSH levels (Figure 7F, S4A, and S4B), which mirrored the effects of glutaminase inhibition by BPTES, consistent with an overall reduction in GSH biosynthesis, as would be predicted

(H–K) Cotreatment with the PDK inhibitor DCA prevents the decrease in phosphorylated RB levels (H) and the increase in ROS levels (I–K) upon pioglitazone treatment. NCI-H2347 cells were treated with vehicle, pioglitazone, DCA, or pioglitazone and DCA for 24 (H) or 12 hr (I)–(K). Then the cells were analyzed by immunoblotting (H) or stained with DCFDA and assayed by FACS (I)–(K).

(L–O) Cotreatment with the β -oxidation inhibitor trimetazidine prevents the decrease in phosphorylated RB levels (L) and the increase in ROS levels (M–O) upon pioglitazone treatment. NCI-H2347 cells were treated with vehicle, pioglitazone, trimetazidine, or pioglitazone and trimetazidine for 24 (L) or 12 hr (M)–(O). Then the cells were analyzed by immunoblot (L) or stained with DCFDA and assayed by FACS (M)–(O).



(legend on next page)

to follow a suppression of glutamate synthesis. Furthermore, we demonstrate that pioglitazone markedly reduced the flux from [U- 13 C] glutamine in the medium to intracellular GSH within 12 hr of treatment and also mirrored the effects of glutaminase inhibition by BPTES (Figure S4C). Also, we found that inhibition of fatty acid oxidation with trimetazidine prevented the reduction of glutamate synthesis from glutamine (Figure S4D). When considered together with our other observations, these results suggest that the metabolic changes induced by PPAR γ activation impair glutaminolysis, reducing levels of glutamate and GSH. According to this model, the reduction in GSH levels diminishes the capacity of the cancer cells to detoxify ROS. To corroborate this hypothesis, we tested if glutaminase inhibition or glutamine withdrawal inhibition would have similar effects in NCI-H2347 cells as pioglitazone treatment. The glutaminase inhibitor BPTES also suppressed both reduced and total levels of GSH, and combining pioglitazone with BPTES enhanced these effects (Figure 7F). Also, we found that glutamine withdrawal resulted in a marked increase of ROS levels within 12 hr (Figures 7G and 7H) and led to a time-dependent decrease of phosphorylated RB levels (Figure 7I). Likewise, glutaminase inhibition with BPTES caused upregulation of ROS levels (Figures 7J–7M), which was suppressed by NAC (Figures S4E–S4H), led to RB hypophosphorylation (Figure 7N), which was prevented by cotreatment with NAC (Figure S4I) and resulted in a marked inhibition of the growth of xenograft tumors in vivo (Figure S4J). Thus, glutaminase inhibition phenocopies essentially all effects of pioglitazone treatment, which supports our mechanistic model for the effects of PPAR γ activation on cancer cell metabolism and cell proliferation.

DISCUSSION

Tumor-suppressive functions have been proposed for PPAR γ and its agonists in a variety of common cancers such as breast, colorectal, and lung cancer (Koeffler, 2003; Peters et al., 2012). For lung cancer, activation of PPAR γ with TZDs was shown to be effective in inhibiting tumor growth of PPAR γ -expressing human cancer cells in vitro and in vivo (Jeong et al., 2012). Importantly, combination of TZDs with platinum-based chemotherapy in mouse models of lung adenocarcinoma (Girnun et al., 2008) was shown to be highly effective in reducing tumor growth,

and upregulation of PPAR γ expression (and its target genes) has been linked to the antitumorigenic effects of Myc oncogene ablation in a lung adenocarcinoma mouse model (Soucek et al., 2013). In this vein, we found that high expression of PPAR γ in early stage lung adenocarcinomas predicts longer overall and/or progression-free survival in independent patient cohorts (Figures S4A–S4C). Collectively, these observations suggest an antitumorigenic role for PPAR γ in lung adenocarcinoma.

Several mechanisms have been proposed for growth inhibition of PPAR γ and TZDs (Koeffler, 2003; Peters et al., 2012), but despite the established role of PPAR γ as a key regulator of glucose and fatty acid metabolism in normal tissue, specific changes in cancer metabolism have not been proposed previously as a key mechanism for the antitumorigenic actions of PPAR γ . Our findings show that PPAR γ activation causes changes to glucose, fatty acid, and glutamine metabolism that ultimately result in ROS-mediated RB hypophosphorylation, which can be prevented either by suppressing the PPAR γ target PDK4 or by inhibiting β -oxidation. Thus, we propose a mechanism by which PPAR γ -induced metabolic changes elicit direct effects on cell-cycle progression. Importantly, our study demonstrates an essential role of ROS in this metabolic regulation of cell proliferation and thus highlights a key role of ROS in the integration of metabolism and proliferation. Furthermore, we establish a proof of principle that this pathway may be therapeutically targeted with FDA-approved antidiabetic drugs such as pioglitazone and troglitazone. An altered redox state has long been observed in cancer cells, making transformed cells vulnerable to further increases in ROS levels and highly dependent on ROS detoxification systems (Cairns et al., 2011; Trachootham et al., 2009). In this context, our findings suggest that modulating glucose, lipid, and glutamine metabolism with nuclear receptor ligands, alone or in combination with existing therapies, may provide an avenue for the development of novel cancer treatment strategies.

EXPERIMENTAL PROCEDURES

Cell Culture

NCI-H2347 and NCI-H1993 cells were cultured in RPMI with 5% fetal bovine serum and incubated at 37°C at 5% CO $_2$. For all experiments, cells were seeded one day prior to treatment.

Figure 7. PPAR γ Activation Alters Glucose and Glutamine Metabolism in NCI-H2347 Cells to Culminate in Suppressed GSH Abundance

- (A) Glucose consumption and lactate secretion in vehicle and pioglitazone (Pio)-treated NCI-H2347 cells. Data are the average and SD of three independent cultures. (B) Isotope tracing diagram illustrating the supply of carbon from glucose to the TCA cycle. Blue circles are 13 C originating from [U- 13 C]glucose. Open circles are unlabeled carbon (12 C). Abbreviations: PDH, pyruvate dehydrogenase; PDK4, pyruvate dehydrogenase kinase-4; aKG, α -ketoglutarate, OAA, oxaloacetate. (C and D) Mass isotopomer distribution for citrate in vehicle and pioglitazone-treated cells cultured with [U- 13 C]glucose (C). Isotopomers are shown as mass (m) plus additional mass units from 13 C. m+2 fraction of additional metabolites related to the TCA cycle (D). Data are the average and SD of three independent cultures. (E) Time-dependent production of [U- 13 C]glutamate in control and pioglitazone-treated cells cultured with [U- 13 C]glutamine. Each time point is derived from an independent culture. (F) GSH abundance in control cells and in cells treated with pioglitazone, BPTES, or pioglitazone and BPTES. Data are the average and SD of three independent cultures. *p < 0.05; **p < 0.005. (G and H) Glutamine depletion causes a rapid increase in ROS levels. NCI-H2347 cells were grown for 12 hr in the presence (Gln+) (G) or absence (Gln-) (H) of glutamine in the medium, stained with DCFDA, and assayed by FACS. (I) Glutamine depletion causes a decrease in phosphorylated RB levels. NCI-H2347 cells were grown for 1, 2, 4, 6, 12, or 24 hr in the presence (+) or absence (–) of glutamine in the medium. (J–M) Glutaminase inhibition by BPTES causes an increase in ROS levels. NCI-H2347 cells were treated for 12 hr with vehicle (J), pioglitazone (K), BPTES (L), or BPTES and pioglitazone (M), and stained with DCFDA and assayed by FACS. (N) Glutaminase inhibition with BPTES causes a decrease in phosphorylated RB levels. NCI-H2347 cells were treated with vehicle, pioglitazone, BPTES, or pioglitazone and BPTES for 24 hr.

ChIP-Seq

We generated PPAR γ -LAP BAC transgenic NCI-H2347 and NCI-H1993 cell lines using the BAC-transgenesis approach to perform ChIP as previously described (Hua et al., 2009; Kittler et al., 2013; Poser et al., 2008). Barcoded libraries of ChIP and input DNA were generated with the SOLiD Fragment Library Barcoding Kit (Applied Biosystems), and 35-nt single-end reads were generated with the SOLiD4 HQ system (Applied Biosystems). PPAR γ -bound regions were identified as genomic regions with a significant read enrichment and binding peak profile in the PPAR γ reads over the input reads by using the Model-based Analysis of ChIP-Seq (MACS) (Poser et al., 2008) software tool (v.1.4.2) with 1% FDR. De novo motif discovery analysis for shared PPAR γ -bound regions was performed with the Multiple EM for Motif Elicitation (MEME) software tool (Bailey et al., 2006). We analyzed the enrichment of known transcription factor motifs by determining the frequency of known motifs in PPAR γ -bound regions and for 75,000 random sets of the same sample size by using Motif Scanner (Aerts et al., 2003). We performed pathway enrichment analysis on shared PPAR γ target genes in NCI-H2347 and NCI-H1993 cells. Gene sets used for this analysis were obtained from Merico et al. (2010). Enrichment p values were calculated using hypergeometric test, and significantly enriched pathways (FDR \leq 1%) were used to construct an enrichment map.

Quantitative PCR and Microarray Analysis

Total DNA-free RNA was prepared and used for quantitative real time PCR using SYBR[®] Green. Quantification was performed with the comparative C_T method ($\Delta\Delta C_T$). Microarray analysis was performed with the Illumina Human HT12v4.0 Expression Beadchip (Illumina, Inc.). Linear models for microarray data (LIMMA) (Smyth, 2004) was used to identify genes that showed significant expression changes between the pioglitazone treated and vehicle samples for each time point (cut-off: adjusted p < 0.05 and log₂-fold change of \geq 1 and \leq -1). Clustering analysis was performed as hierarchical clustering with Euclidean distance metric and "agglomerative average" method, or centroid based clustering (k means clustering). To determine the enrichment of gene sets at the top or bottom of a ranked list of differentially regulated genes upon pioglitazone treatment, we performed GSEA using the time course expression data and a priori defined gene sets.

Cell-Cycle and ROS Level Analysis

DNA content analysis was performed by FACS of \sim 10,000 propidium-iodide-stained cells. Intracellular ROS and mitochondrial superoxide was detected by FACS of \sim 10,000 cells with ROS-sensitive fluorescent probes (DCFDA and MitoSOX).

Xenograft Experiments

NCI-H2347 cells (2×10^6 /site, two sites/animal) were injected subcutaneously into both flank regions of Female athymic NOD SCID mice. When tumors became visible, treatment (intraperitoneal [i.p.]) was started with various compounds or DMSO (vehicle) every other day for a total of four to five injections. Tumor volume was calculated as $(width) \times (width) \times (length)/2$, where length is greater than width. All mouse experiments were in compliance with UT Southwestern Institutional Animal Care and Use Committee (IACUC) policies.

Immunohistochemistry

Tumors harvested from anesthetized mice were processed for immunohistochemistry by standard procedures. Mouse anti-sera and subsequent biotin/streptavidin-fluorescein detection of bound primary was used for Ki-67 immunolabeling. Terminal deoxynucleotidyltransferase-mediated UTP end label (TUNEL) staining for apoptotic cells was done according to the protocol supplied with DeadEnd Fluorometric TUNEL System (Promega). Apoptotic cells were labeled with fluorescein, and the sections were counterstained with propidium iodide. Image acquisition was performed with a DM5500B fluorescent microscope (Leica).

Metabolic Assays

For the analysis of glucose metabolism, NCI-H2347 cells were incubated with DMSO or pioglitazone for 6 hr; medium was then replaced with medium containing 25 mM [U-¹³C]glucose. After 6 hr of labeling, medium was removed for glucose and lactate analysis as previously described (Yang et al., 2009). For analysis by mass spectrometry, the cells were processed as previously

described (Cheng et al., 2011). To quantify the production of ¹³C-glutamate from ¹³C-glutamine, cells were cultured in medium containing 2mM [U-¹³C] glutamine and lysed at several time points over 60 min. GSH quantitation was performed using ultra high performance liquid chromatography. For measuring flux of extracellular glutamine to GSH, cells were cultured in medium containing 2mM [U-¹³C]glutamine and lysed after 6, 12, or 24 hr. The measurement of GSH was performed using a liquid chromatography-tandem mass spectrometry approach.

Statistical Analysis

We tested the statistical significance between tumor volumes by calculating p values for 10,000 permutations with the *compareGrowthCurves* function from the Statistical Modeling package, *statmod*, available from the R Project (<http://www.r-project.org>). For other experiments, statistical significance was determined by a two-tailed unpaired Student's t test. p values < 0.05 were considered statistically significant.

ACCESSION NUMBERS

ChIP-seq and microarray data has been deposited with NCBI Gene Expression Omnibus (GEO) (accession number GSE59736).

SUPPLEMENTAL INFORMATION

Supplemental Information includes five figures, four tables, and Supplemental Experimental Procedures and can be found with this article online at <http://dx.doi.org/10.1016/j.cmet.2014.08.003>.

AUTHOR CONTRIBUTIONS

N.S. performed and analyzed most of the experiments; R.K.K. performed all computational analyses related to ChIP-seq and expression profiling; D.K.S., J.S., Z.H., and H.N. performed and analyzed experiments; S.W. and C.G.H. performed experiments; R.C. and K.E.H. analyzed data; R.J.D. designed and analyzed the metabolomic experiments and wrote the manuscript. R.K. conceived, designed, and directed this study; analyzed data; and wrote the manuscript.

ACKNOWLEDGMENTS

We would like to thank David Mangelsdorf and John Minna and all other colleagues of the Multi-Investigator Research Awards RP101251 and RP120732 of the Cancer Prevention and Research Institute of Texas (CPRIT) for sharing preliminary data and reagents and discussion of this manuscript. We are grateful to John Shelton, Claire Klimko, the Simmons Comprehensive Cancer Center Microarray Core, and the McDermott Sequencing Core at UT Southwestern for technical assistance. We thank Takashi Tsukamoto for sharing BPTES. This study was supported by grants from CPRIT (RP101251-P06 and RP120732-P3 to R.K.; RP130272-02 to R.J.D.) and the National Institutes of Health (R01 CA157996 to R.J.D.). Metabolomics was supported in part by a gift from Jerry and Emy Lou Baldrige. R.K. is a John L. Roach Scholar in Biomedical Research and a CPRIT Scholar in Cancer Research.

Received: June 4, 2014

Revised: July 27, 2014

Accepted: August 4, 2014

Published: September 25, 2014

REFERENCES

- Aerts, S., Thijs, G., Coessens, B., Staes, M., Moreau, Y., and De Moor, B. (2003). Toucan: deciphering the cis-regulatory logic of coregulated genes. *Nucleic Acids Res.* 31, 1753–1764.
- Alberts, A.S., Thorburn, A.M., Shenolikar, S., Mumby, M.C., and Feramisco, J.R. (1993). Regulation of cell cycle progression and nuclear affinity of the retinoblastoma protein by protein phosphatases. *Proc. Natl. Acad. Sci. USA* 90, 388–392.

- Andrews, M.T., Squire, T.L., Bowen, C.M., and Rollins, M.B. (1998). Low-temperature carbon utilization is regulated by novel gene activity in the heart of a hibernating mammal. *Proc. Natl. Acad. Sci. USA* 95, 8392–8397.
- Avni, D., Yang, H., Martelli, F., Hofmann, F., ElShamy, W.M., Ganesan, S., Scully, R., and Livingston, D.M. (2003). Active localization of the retinoblastoma protein in chromatin and its response to S phase DNA damage. *Mol. Cell* 12, 735–746.
- Bailey, T.L., Williams, N., Misleh, C., and Li, W.W. (2006). MEME: discovering and analyzing DNA and protein sequence motifs. *Nucleic Acids Res.* 34 (Web Server issue), W369–W373.
- Cairns, R.A., Harris, I.S., and Mak, T.W. (2011). Regulation of cancer cell metabolism. *Nat. Rev. Cancer* 11, 85–95.
- Cheng, T., Sudderth, J., Yang, C., Mullen, A.R., Jin, E.S., Matés, J.M., and DeBerardinis, R.J. (2011). Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. *Proc. Natl. Acad. Sci. USA* 108, 8674–8679.
- Christofk, H.R., Vander Heiden, M.G., Harris, M.H., Ramanathan, A., Gerszten, R.E., Wei, R., Fleming, M.D., Schreiber, S.L., and Cantley, L.C. (2008). The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. *Nature* 452, 230–233.
- DeBerardinis, R.J., Mancuso, A., Daijkin, E., Nissim, I., Yudkoff, M., Wehrli, S., and Thompson, C.B. (2007). Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. *Proc. Natl. Acad. Sci. USA* 104, 19345–19350.
- DeBerardinis, R.J., Lum, J.J., Hatzivassiliou, G., and Thompson, C.B. (2008). The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. *Cell Metab.* 7, 11–20.
- Girnun, G.D., Chen, L., Silvaggi, J., Drapkin, R., Chiriac, L.R., Padera, R.F., Upadhyay, R., Vafai, S.B., Weissleder, R., Mahmood, U., et al. (2008). Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. *Clin. Cancer Res.* 14, 6478–6486.
- Grassian, A.R., Metallo, C.M., Coloff, J.L., Stephanopoulos, G., and Brugge, J.S. (2011). Erk regulation of pyruvate dehydrogenase flux through PDK4 modulates cell proliferation. *Genes Dev.* 25, 1716–1733.
- Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next generation. *Cell* 144, 646–674.
- Hensley, C.T., Wasti, A.T., and DeBerardinis, R.J. (2013). Glutamine and cancer: cell biology, physiology, and clinical opportunities. *J. Clin. Invest.* 123, 3678–3684.
- Holness, M.J., Kraus, A., Harris, R.A., and Sugden, M.C. (2000). Targeted up-regulation of pyruvate dehydrogenase kinase (PDK)-4 in slow-twitch skeletal muscle underlies the stable modification of the regulatory characteristics of PDK induced by high-fat feeding. *Diabetes* 49, 775–781.
- Hsu, P.P., and Sabatini, D.M. (2008). Cancer cell metabolism: Warburg and beyond. *Cell* 134, 703–707.
- Hua, S., Kittler, R., and White, K.P. (2009). Genomic antagonism between retinoic acid and estrogen signaling in breast cancer. *Cell* 137, 1259–1271.
- Hue, L., and Taegtmeier, H. (2009). The Randle cycle revisited: a new head for an old hat. *Am. J. Physiol. Endocrinol. Metab.* 297, E578–E591.
- Jeong, Y., Xie, Y., Lee, W., Bookout, A.L., Girard, L., Raso, G., Behrens, C., Wistuba, I.I., Gadzar, A.F., Minna, J.D., and Mangelsdorf, D.J. (2012). Research resource: Diagnostic and therapeutic potential of nuclear receptor expression in lung cancer. *Mol. Endocrinol.* 26, 1443–1454.
- Kittler, R., Zhou, J., Hua, S., Ma, L., Liu, Y., Pendleton, E., Cheng, C., Gerstein, M., and White, K.P. (2013). A comprehensive nuclear receptor network for breast cancer cells. *Cell Rep.* 3, 538–551.
- Kliwer, S.A., and Willson, T.M. (1998). The nuclear receptor PPAR γ - bigger than fat. *Curr. Opin. Genet. Dev.* 8, 576–581.
- Koeffler, H.P. (2003). Peroxisome proliferator-activated receptor gamma and cancers. *Clin. Cancer Res.* 9, 1–9.
- Koppenol, W.H., Bounds, P.L., and Dang, C.V. (2011). Otto Warburg's contributions to current concepts of cancer metabolism. *Nat. Rev. Cancer* 11, 325–337.
- Le, A., Lane, A.N., Hamaker, M., Bose, S., Gouw, A., Barbi, J., Tsukamoto, T., Rojas, C.J., Slusher, B.S., Zhang, H., et al. (2012). Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. *Cell Metab.* 15, 110–121.
- Lefterova, M.I., Zhang, Y., Steger, D.J., Schupp, M., Schug, J., Cristancho, A., Feng, D., Zhuo, D., Stoeckert, C.J., Jr., Liu, X.S., and Lazar, M.A. (2008). PPAR γ and C/EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale. *Genes Dev.* 22, 2941–2952.
- Merico, D., Isserlin, R., Stueker, O., Emili, A., and Bader, G.D. (2010). Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. *PLoS ONE* 5, e13984.
- Nielsen, R., Pedersen, T.A., Hagenbeek, D., Moulos, P., Siersbaek, R., Megens, E., Denissov, S., Børgesen, M., Francoijs, K.J., Mandrup, S., and Stunnenberg, H.G. (2008). Genome-wide profiling of PPAR γ :RXR and RNA polymerase II occupancy reveals temporal activation of distinct metabolic pathways and changes in RXR dimer composition during adipogenesis. *Genes Dev.* 22, 2953–2967.
- Peters, J.M., Shah, Y.M., and Gonzalez, F.J. (2012). The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. *Nat. Rev. Cancer* 12, 181–195.
- Poser, I., Sarov, M., Hutchins, J.R., Hériché, J.K., Toyoda, Y., Pozniakovskiy, A., Weigl, D., Nitzsche, A., Hegemann, B., Bird, A.W., et al. (2008). BAC TransGeneOmics: a high-throughput method for exploration of protein function in mammals. *Nat. Methods* 5, 409–415.
- Robinson, M.M., McBryant, S.J., Tsukamoto, T., Rojas, C., Ferraris, D.V., Hamilton, S.K., Hansen, J.C., and Curthoys, N.P. (2007). Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES). *Biochem. J.* 406, 407–414.
- Smyth, G.K. (2004). Linear models and empirical bayes methods for assessing differential expression in microarray experiments. *Stat. Appl. Genet. Mol. Biol.* 3, <http://dx.doi.org/10.2202/1544-6115.1027>.
- Soucek, L., Whitfield, J.R., Sodir, N.M., Massó-Vallés, D., Serrano, E., Karnezis, A.N., Swigart, L.B., and Evan, G.I. (2013). Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. *Genes Dev.* 27, 504–513.
- Strand, D.W., Jiang, M., Murphy, T.A., Yi, Y., Konvins, K.C., Franco, O.E., Wang, Y., Young, J.D., and Hayward, S.W. (2012). PPAR γ isoforms differentially regulate metabolic networks to mediate mouse prostatic epithelial differentiation. *Cell Death Dis.* 3, e361.
- Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., and Mesirov, J.P. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. USA* 102, 15545–15550.
- Thangavelu, K., Pan, C.Q., Karlberg, T., Balaji, G., Uttamchandani, M., Suresh, V., Schüler, H., Low, B.C., and Sivaraman, J. (2012). Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism. *Proc. Natl. Acad. Sci. USA* 109, 7705–7710.
- Trachootham, D., Alexandre, J., and Huang, P. (2009). Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? *Nat. Rev. Drug Discov.* 8, 579–591.
- Vander Heiden, M.G., Cantley, L.C., and Thompson, C.B. (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation. *Science* 324, 1029–1033.
- Vander Heiden, M.G., Christofk, H.R., Schuman, E., Subtelny, A.O., Sharfi, H., Harlow, E.E., Xian, J., and Cantley, L.C. (2010). Identification of small molecule inhibitors of pyruvate kinase M2. *Biochem. Pharmacol.* 79, 1118–1124.
- Warburg, O. (1956). On the origin of cancer cells. *Science* 123, 309–314.
- Willson, T.M., Lambert, M.H., and Kliwer, S.A. (2001). Peroxisome proliferator-activated receptor gamma and metabolic disease. *Annu. Rev. Biochem.* 70, 341–367.
- Yang, C., Sudderth, J., Dang, T., Bachoo, R.M., McDonald, J.G., and DeBerardinis, R.J. (2009). Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. *Cancer Res.* 69, 7986–7993.